Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$92.1M
1 round on record
Latest round
$92.1M
Venture round · May 2021 · 5 yr ago
Team
17
US Form 5500 (plan participants) · Dec 2025 · -6% in a year
Backers
1
Lumira Ventures
The money's age
Long since its last round
64 months since the last round · not hiring
Momentum
0/100
no fresh signals
Funding rounds
RoundDateAmountInvestorsSource
Venture round May 2021 $92.1M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity BIOTHERYX, INC. sec
Founders and leadersfrom filings, registers and the company's site
Kyle ChanExecutive OfficerSEC Form D
Dung ThaiExecutive OfficerSEC Form D
Jaime DonadioExecutive OfficerSEC Form D
David StirlingExecutive Officer, DirectorSEC Form D
Frank MercurioExecutive OfficerSEC Form D
Robert WilliamsonExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Similar startupsby what they do, their industry and backers
AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.
Octagon TherapeuticsVenture round $11M · 2 yr ago • Founded 2016 • 11-50 employees
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
QuantX Biosciences1-10 employees
At QuantX, we leverage the power of computation and modeling to accelerate the discovery of superior medicines for validated targets in…
Gene therapy for advanced coronary artery disease. XyloCor Therapeutics is focused on improving the lives of patients through our…
Congruence11-50 employees
We are a drug discovery company that is uniquely harnessing the power of protein dynamics, biophysics, machine learning and computational…
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling…

Overview

Degrading proteins.Saving lives.. Biotheryx is advancing a portfolio of first-in-class protein degraders, with an initial focus on validated targets in cancer and inflammatory disease.

People

Kyle Chan
Executive Officer
Dung Thai
Executive Officer
Jaime Donadio
Executive Officer
David Stirling
Executive Officer, Director
Frank Mercurio
Executive Officer
Robert Williamson
Executive Officer, Director
Jack Noelke
Director
Christopher Devine
Director
Louis DeGennaro
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Diego United States
HQ
200-500 est. staff

Financials

Total raised
$92.1M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2021 $92.1M Details